Ohmachi, Ken
Ogura, Michinori
Suehiro, Youko
Ando, Kiyoshi
Uchida, Toshiki
Choi, Ilseung
Ogawa, Yoshiaki
Kobayashi, Miki
Fukino, Koichi
Yokoi, Yuki
Okamura, Jun
Article History
Received: 26 September 2018
Revised: 13 March 2019
Accepted: 14 March 2019
First Online: 26 March 2019
Compliance with ethical standards
:
: K.O., M.O., Y.S., K.A., T.U., I.C., Y.O., M.K. and J.O. have received research Grants from AstraZeneca. K.F. was an employee of AstraZeneca and owned stock/stock options in the company at the time of the study. Y.Y. is an employee of AstraZeneca and owns stock/stock options in the company. This study was designed under the responsibility of MedImmune, the global biologics R&D arm of AstraZeneca, the study was funded by MedImmune, and the study drug was provided by MedImmune. Each author had full access to the data, made substantial contributions to the drafting and/or revision of this manuscript, and granted approval for the submission of this paper. No author received an honorarium or other form of financial support related to the development of this manuscript.